{"id":1016,"date":"2026-05-06T05:50:15","date_gmt":"2026-05-06T05:50:15","guid":{"rendered":"https:\/\/ulemnrme.a2hosted.com\/wordpress\/?page_id=1016"},"modified":"2026-05-30T22:49:55","modified_gmt":"2026-05-30T22:49:55","slug":"menopause","status":"publish","type":"page","link":"https:\/\/diaendo.com\/index.php\/menopause\/","title":{"rendered":"Menopause &#038; Perimenopause"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row full_width=\u201dstretch_row\u201d css=\u201d.vc_custom_mp_hdr{background-color: #149d79 !important; padding-top: 28px !important; padding-bottom: 24px !important;}\u201d][vc_column][vc_custom_heading text=\u201dPatient Education \u00b7 Endocrinology\u201d font_container=\u201dtag:p|font_size:11px|text_align:left|color:%23ffffff\u201d use_theme_fonts=\u201dyes\u201d][vc_custom_heading text=\u201dMenopause &amp; Perimenopause\u201d font_container=\u201dtag:h1|font_size:44px|text_align:left|color:%23ffffff|line_height:1.1\u2033 use_theme_fonts=\u201dyes\u201d][vc_custom_heading text=\u201dA guide to understanding the menopause transition, the symptoms it brings, and the treatments \u2014 including hormone therapy \u2014 that we use to help our patients live well.\u201d font_container=\u201dtag:p|font_size:15px|text_align:left|color:%23ffffff\u201d use_theme_fonts=\u201dyes\u201d][\/vc_column][\/vc_row][vc_row][vc_column width=\u201d1\/1\u2033][vc_column_text]<\/p>\n<style>.de-toc{background:transparent;border:none;border-radius:0;padding:0;box-shadow:none;margin:0 0 6px;}.de-toc-label{font-size:.74rem;font-weight:700;letter-spacing:.12em;text-transform:uppercase;color:#149d79;margin:0 0 12px;text-align:center;}.de-toc-inner{display:flex;flex-wrap:wrap;gap:10px;justify-content:center;}.de-toc-pill{display:inline-block;font-size:.86rem;font-weight:600;line-height:1;padding:9px 16px;border:1.5px solid #149d79;border-radius:999px;color:#149d79;text-decoration:none !important;white-space:nowrap;transition:background .15s ease,color .15s ease;}.de-toc-pill:hover{background:#149d79;color:#fff !important;}.de-section{scroll-margin-top:30px;}@media(max-width:680px){.de-toc-inner{justify-content:flex-start;overflow-x:auto;flex-wrap:nowrap;-webkit-overflow-scrolling:touch;}.de-toc-pill{font-size:.8rem;padding:8px 13px;}}<\/style>\n<div class=\"de-toc\">\n<p class=\"de-toc-label\">On this page<\/p>\n<div class=\"de-toc-inner\"><a class=\"de-toc-pill\" href=\"#sec-the-menopause-spectrum\">The Menopause Spectrum<\/a><a class=\"de-toc-pill\" href=\"#sec-premature-and-early-menopause\">Premature & Early Menopause<\/a><a class=\"de-toc-pill\" href=\"#sec-the-range-of-symptoms\">The Range of Symptoms<\/a><a class=\"de-toc-pill\" href=\"#sec-why-menopause-matters-beyond-symptoms\">Why Menopause Matters Beyond Symptoms<\/a><a class=\"de-toc-pill\" href=\"#sec-our-philosophy\">Our Philosophy<\/a><a class=\"de-toc-pill\" href=\"#sec-why-we-advocate-for-hormone-therapy\">Why We Advocate for Hormone Therapy<\/a><\/div>\n<\/div>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row css=\u201d.vc_custom_mp_body{padding-top:50px !important;padding-bottom:60px !important;}\u201d][vc_column width=\u201d1\/1\u2033][vc_column_text]<\/p>\n<p class=\"de-intro\">If you have questions about perimenopause or menopause, or would like to discuss treatment options including hormone therapy, we invite you to <a href=\"\/contact\">contact our office<\/a>. All care is individualized to your specific history, risk profile, and goals.<\/p>\n<p class=\"de-section\" id=\"sec-the-menopause-spectrum\">The Menopause Spectrum<\/p>\n<p class=\"de-q\">What is menopause?<\/p>\n<div class=\"de-a\">\n<p>Menopause is the point at which a woman\u2019s ovaries stop releasing eggs and stop producing significant amounts of estrogen and progesterone. It is defined retrospectively \u2014 once 12 consecutive months have passed without a menstrual period. In the United States and Europe, the average age of menopause is around 51 to 52.<\/p>\n<p>The current European Society of Endocrinology guideline frames menopause as a <strong>spectrum<\/strong> rather than a single event. That spectrum includes the perimenopause (the transition leading up to the final menstrual period), the menopause itself, and the postmenopause that follows. Symptoms can begin years before the last period and can persist for years afterward.<\/p>\n<div class=\"de-callout\">\n<strong>The old idea that women go to bed premenopausal and wake up postmenopausal is wrong.<\/strong> Ovarian function declines gradually, sometimes over a decade, and the hormonal changes affect virtually every organ system \u2014 not just reproduction.<\/div>\n<\/div>\n<p class=\"de-q\">What is perimenopause, and why is it so often missed?<\/p>\n<div class=\"de-a\">\n<p>Perimenopause is the transition phase. Ovarian function is declining but has not yet stopped \u2014 and the decline is not steady. Hormone levels swing unpredictably from one day to the next. A woman may have a normal hormone panel one week and a strikingly abnormal one the next, even when her symptoms are obvious and unrelenting.<\/p>\n<p>Perimenopause typically begins in a woman\u2019s 40s but can start earlier. It is often where the most disruptive symptoms appear \u2014 irregular bleeding, hot flashes, sleep disturbance, mood changes, brain fog, joint aches \u2014 and it is often the phase that gets misdiagnosed. Women are sent to a sleep specialist for insomnia, a psychiatrist for anxiety, a rheumatologist for joint pain, when in fact one underlying hormonal shift is driving all of it.<\/p>\n<p>As Yale gynecologist Mary Jane Minkin has put it, <em>menopause is the easy part \u2014 perimenopause is the tricky part<\/em>. We agree, and we approach perimenopausal symptoms aggressively rather than telling women to \u201cwait it out.\u201d<\/p>\n<\/div>\n<p class=\"de-q\">When should I be evaluated, and do I need blood tests?<\/p>\n<div class=\"de-a\">\n<p>For a woman <strong>over 45<\/strong> with typical menopausal symptoms, the diagnosis is clinical. No blood test is required. FSH and estradiol fluctuate so much during this period that a single normal value does not rule out perimenopause and a single high value does not confirm it.<\/p>\n<p>For a woman <strong>40 to 45<\/strong> with menstrual irregularity or vasomotor symptoms, biochemical testing can be considered if there is doubt about the diagnosis. For any woman <strong>under 40<\/strong> with menstrual irregularity, unexplained subfertility, or hot flashes, evaluation is mandatory \u2014 premature ovarian insufficiency must be ruled out, because the long-term health implications are significant and treatment should not be delayed.<\/p>\n<div class=\"table-wrap\">\n<table>\n<thead>\n<tr>\n<th>Age<\/th>\n<th>Approach<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Over 45<\/td>\n<td>Clinical diagnosis; biochemical testing not required<\/td>\n<\/tr>\n<tr>\n<td>40 to 45<\/td>\n<td>Clinical diagnosis usually sufficient; FSH testing if uncertainty<\/td>\n<\/tr>\n<tr>\n<td>Under 40<\/td>\n<td>Always evaluate. FSH, estradiol, and a structured workup for premature ovarian insufficiency<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<p class=\"de-section\" id=\"sec-premature-and-early-menopause\">Premature &amp; Early Menopause<\/p>\n<p class=\"de-q\">What if I\u2019m under 40 with menopausal symptoms?<\/p>\n<div class=\"de-a\">\n<p><strong>Premature ovarian insufficiency (POI)<\/strong> is the loss of ovarian function before age 40. It affects roughly 1 to 3% of women. <strong>Early menopause<\/strong> refers to menopause occurring between 40 and 45. Both are clinically important because the body is exposed to estrogen deficiency for many additional years compared to the average woman, and that deficiency drives measurable increases in cardiovascular disease, osteoporosis, cognitive decline, depression, and overall mortality.<\/p>\n<p>The diagnosis of POI is made with one FSH greater than 25 IU\/L in the right clinical context, or two such measurements at least four weeks apart when the picture is less clear. Once confirmed, additional workup is appropriate \u2014 including genetic testing where available, autoimmune screens, thyroid function, and bone densitometry.<\/p>\n<div class=\"de-callout\">\n<strong>Hormone replacement is the standard of care in POI<\/strong> regardless of whether symptoms are present. The benefits of replacing estrogen at this age clearly outweigh the risks, and treatment should generally continue at least until the average age of natural menopause (around 51) and then be reassessed.<\/div>\n<div style=\"border-top: 2px solid #1a1a1a; margin-bottom: 32px; position: relative;\"><span style=\"position: absolute; top: -12px; left: 0; background: #1a1a1a; color: #fff; font-size: 10px; font-weight: 700; letter-spacing: 0.18em; text-transform: uppercase; padding: 3px 12px; border-radius: 0 3px 3px 0;\">Symptoms \u2014 What Menopause Actually Feels Like<\/span><\/div>\n<\/div>\n<p class=\"de-section\" id=\"sec-the-range-of-symptoms\">The Range of Symptoms<\/p>\n<p class=\"de-q\">What are the most common symptoms?<\/p>\n<div class=\"de-a\">\n<p>Symptoms cluster across several body systems. Vasomotor symptoms \u2014 hot flashes and night sweats \u2014 are the most recognized, but they are far from the whole story. Most women experience symptoms in multiple domains, and the symptoms often interact: poor sleep worsens mood, mood worsens cognition, and so on.<\/p>\n<div style=\"display: grid; grid-template-columns: 1fr 1fr; gap: 14px; margin: 16px 0;\">\n<div class=\"de-card\">\n<p style=\"margin-top:0;font-weight:600;color:#1a1a1a;font-size:1rem;\">Vasomotor<\/p>\n<ul>\n<li>Hot flashes<\/li>\n<li>Night sweats<\/li>\n<li>Palpitations<\/li>\n<li>Skin flushing<\/li>\n<\/ul>\n<\/div>\n<div class=\"de-card\">\n<p style=\"margin-top:0;font-weight:600;color:#1a1a1a;font-size:1rem;\">Sleep &amp; Cognition<\/p>\n<ul>\n<li>Insomnia and frequent awakening<\/li>\n<li>\u201cBrain fog\u201d and concentration difficulty<\/li>\n<li>Memory lapses, especially verbal<\/li>\n<li>Daytime fatigue<\/li>\n<\/ul>\n<\/div>\n<div class=\"de-card\">\n<p style=\"margin-top:0;font-weight:600;color:#1a1a1a;font-size:1rem;\">Mood<\/p>\n<ul>\n<li>Low mood and tearfulness<\/li>\n<li>New or worsening anxiety<\/li>\n<li>Irritability<\/li>\n<li>Loss of confidence<\/li>\n<\/ul>\n<\/div>\n<div class=\"de-card\">\n<p style=\"margin-top:0;font-weight:600;color:#1a1a1a;font-size:1rem;\">Urogenital &amp; Sexual<\/p>\n<ul>\n<li>Vaginal dryness and burning<\/li>\n<li>Painful intercourse<\/li>\n<li>Recurrent urinary tract infections<\/li>\n<li>Decreased libido<\/li>\n<\/ul>\n<\/div>\n<div class=\"de-card\">\n<p style=\"margin-top:0;font-weight:600;color:#1a1a1a;font-size:1rem;\">Musculoskeletal<\/p>\n<ul>\n<li>Joint aches and stiffness<\/li>\n<li>Muscle pain<\/li>\n<li>New headaches or migraines<\/li>\n<\/ul>\n<\/div>\n<div class=\"de-card\">\n<p style=\"margin-top:0;font-weight:600;color:#1a1a1a;font-size:1rem;\">Other<\/p>\n<ul>\n<li>Weight gain, particularly central<\/li>\n<li>Skin and hair changes<\/li>\n<li>Menstrual irregularity (perimenopause)<\/li>\n<li>Heart palpitations<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<p class=\"de-q\">How long do symptoms last?<\/p>\n<div class=\"de-a\">\n<p>Vasomotor symptoms \u2014 hot flashes and night sweats \u2014 last on average about 7 years. In about 1 in 10 women they last 12 years or more. They are usually most intense in the year or two after the final menstrual period.<\/p>\n<p>Genitourinary symptoms (vaginal dryness, painful sex, urinary symptoms) follow a different pattern \u2014 they tend to begin later and to <em>persist or progress<\/em> over time rather than resolve. They are caused by ongoing estrogen deficiency in the vaginal and urinary tissues, and they generally do not improve without treatment.<\/p>\n<\/div>\n<div style=\"border-top: 2px solid #1a1a1a; margin-bottom: 32px; position: relative;\"><span style=\"position: absolute; top: -12px; left: 0; background: #1a1a1a; color: #fff; font-size: 10px; font-weight: 700; letter-spacing: 0.18em; text-transform: uppercase; padding: 3px 12px; border-radius: 0 3px 3px 0;\">Long-Term Health Implications<\/span><\/div>\n<p class=\"de-section\" id=\"sec-why-menopause-matters-beyond-symptoms\">Why Menopause Matters Beyond Symptoms<\/p>\n<p class=\"de-q\">How does menopause affect my long-term health?<\/p>\n<div class=\"de-a\">\n<p>Estrogen has receptors in essentially every tissue of the body. When estrogen declines, the consequences extend well beyond hot flashes and mood. The four areas where the long-term impact is most clinically significant are the bones, the cardiovascular system, the brain, and the urogenital tract.<\/p>\n<div style=\"display: flex; gap: 16px; margin: 16px 0; flex-wrap: wrap;\">\n<div style=\"flex: 1 1 30%; min-width: 140px; background: #fff; border: 1px solid #d0dbd7; border-radius: 6px; padding: 16px; text-align: center;\">\n<div style=\"font-size: 1.6rem; font-weight: 700; color: #149d79; line-height: 1;\">~7 yrs<\/div>\n<div style=\"font-size: 11px; color: #777; line-height: 1.4; margin-top: 4px;\">Average duration of hot flashes<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p class=\"de-q\">What happens to bone health after menopause?<\/p>\n<div class=\"de-a\">\n<p>Estrogen is the most important hormonal regulator of bone remodeling in women. With its loss, bone resorption outpaces bone formation, and bone mineral density falls \u2014 most rapidly in the first several years after the final menstrual period. The result is a measurable increase in fracture risk, particularly at the spine and hip.<\/p>\n<p>The protective effect of estrogen on the skeleton has been confirmed across large randomized trials. In the Women\u2019s Health Initiative, hormone therapy reduced hip fractures by roughly a third compared with placebo. We screen high-risk patients with bone density testing and discuss preventive options proactively \u2014 not only after a fracture has already occurred.<\/p>\n<\/div>\n<p class=\"de-q\">Does menopause increase my risk of heart disease?<\/p>\n<div class=\"de-a\">\n<p>Yes, and the change is mediated in part by the loss of estrogen. Before menopause, women have substantially lower rates of coronary disease than men of the same age. That advantage narrows during the menopause transition and largely disappears in the years that follow. Women who go through menopause early \u2014 and especially women with premature ovarian insufficiency \u2014 face the highest risk.<\/p>\n<p>Cardiovascular disease is the leading cause of death in women in the United States. The menopause transition is itself recognized as a window of increased cardiovascular risk by the American Heart Association, and is a critical time to address the modifiable risks: blood pressure, lipids, blood glucose, weight, physical activity, and tobacco use.<\/p>\n<\/div>\n<p class=\"de-q\">Can menopause affect my brain?<\/p>\n<div class=\"de-a\">\n<p>The \u201cbrain fog\u201d that many women describe in perimenopause is real and well-documented. Verbal memory in particular dips during the transition. For most women, cognitive performance returns toward baseline in the years after menopause.<\/p>\n<p>Whether menopause raises long-term risk for Alzheimer\u2019s disease is an active area of research. Two-thirds of Alzheimer\u2019s patients are women, which is not fully explained by longevity alone. Estrogen has known neuroprotective effects in the laboratory. The clinical data on hormone therapy and dementia risk are mixed and depend heavily on age at initiation \u2014 and we do not currently use hormone therapy to prevent or treat dementia. But we do take cognitive symptoms seriously and address the modifiable contributors: sleep, mood, vasomotor symptoms, vascular risk factors, and thyroid function.<\/p>\n<\/div>\n<div style=\"border-top: 2px solid #1a1a1a; margin-bottom: 32px; position: relative;\"><span style=\"position: absolute; top: -12px; left: 0; background: #1a1a1a; color: #fff; font-size: 10px; font-weight: 700; letter-spacing: 0.18em; text-transform: uppercase; padding: 3px 12px; border-radius: 0 3px 3px 0;\">Treatment \u2014 Our Approach by Symptom Domain<\/span><\/div>\n<p class=\"de-section\" id=\"sec-our-philosophy\">Our Philosophy<\/p>\n<p class=\"de-q\">What is your practice\u2019s approach to menopause?<\/p>\n<div class=\"de-a\">\n<p>Our position is straightforward: menopause is an endocrine event, and it deserves endocrine care. We approach it the way we approach any other hormonal deficiency \u2014 with attention to the individual patient, the evidence, the risks, and the benefits, and a willingness to actually treat.<\/p>\n<div class=\"de-callout\" style=\"border-left-width: 4px;\">\n<p style=\"margin-top:0;font-weight:600;color:#1a1a1a;font-size:1rem;\">Where we stand on hormone therapy<\/p>\n<p>For appropriately selected women \u2014 and that includes most women who initiate therapy within 10 years of menopause or before age 60 \u2014 <strong>we are strong advocates for menopausal hormone therapy<\/strong>. The evidence has matured considerably since the early 2000s, when fear-driven prescribing led an entire generation of women to be undertreated. Modern hormone therapy, individualized to the patient, is the most effective treatment available for vasomotor symptoms, prevents bone loss, treats the genitourinary syndrome of menopause, and is safe in the right patient.<\/p>\n<p>That said, we treat the whole patient. Lifestyle, sleep, mood, cardiovascular risk, and bone health all need attention \u2014 and not every patient is a candidate for hormones. We will tell you honestly which category you fall into.<\/p>\n<\/div>\n<\/div>\n<p class=\"de-section\" id=\"sec-sleep-mood-and-cognition\">Sleep, Mood &amp; Cognition<\/p>\n<p class=\"de-q\">How do you treat sleep problems, mood changes, and brain fog?<\/p>\n<div class=\"de-a\">\n<p>Sleep disturbance, mood symptoms, and cognitive complaints in perimenopause and menopause are often <strong>downstream of hormonal change<\/strong>, even when they don\u2019t feel that way. Treating the underlying hormonal shift often resolves several of these complaints at once \u2014 which is why a systemic approach beats symptom-by-symptom treatment.<\/p>\n<div class=\"treatment-item\">\n<div class=\"treatment-name\">Hormone Therapy <span>First-line for moderate to severe symptoms<\/span><\/div>\n<div class=\"treatment-body\">\n<p>Recent meta-analyses show oral estrogen and tibolone reduce depressive symptoms in perimenopausal women, and randomized data support transdermal estradiol with intermittent progesterone for prevention of perimenopausal depression. For sleep disturbance driven by night sweats, hormone therapy is far more effective than any sedative.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<p class=\"de-section\" id=\"sec-cardiovascular-health\">Cardiovascular Health<\/p>\n<p class=\"de-q\">Should I take hormone therapy to protect my heart?<\/p>\n<div class=\"de-a\">\n<p>This is one of the most misunderstood questions in menopause medicine. The short answer is: <strong>we do not start hormone therapy purely to prevent cardiovascular disease<\/strong>. But the long-running concern that hormone therapy <em>causes<\/em> heart disease has been substantially walked back, and for many women hormone therapy is cardiovascularly safe.<\/p>\n<p>Age-stratified analyses of the Women\u2019s Health Initiative and other studies show that women who begin hormone therapy within 10 years of menopause or before age 60 do not have an increased risk of heart disease, and may have a modest reduction in coronary mortality and all-cause mortality. The increased cardiovascular risk seen in the original WHI publication was driven largely by older women \u2014 average age 63, an average of 10 years past menopause \u2014 who would not be considered ideal candidates today.<\/p>\n<p>Practical implications: cardiovascular risk factors (blood pressure, lipids, glucose, weight) should be optimized before starting hormone therapy. In women with elevated cardiovascular risk, transdermal estrogen is preferred over oral. Hormone therapy is not used to prevent stroke, and a personal history of cardiovascular disease changes the calculus considerably.<\/p>\n<\/div>\n<p class=\"de-q\">Can I take hormone therapy if I have diabetes or hypertension?<\/p>\n<div class=\"de-a\">\n<p>Yes, in most cases \u2014 provided these conditions are well-controlled. Well-controlled diabetes is <strong>not a contraindication<\/strong> to hormone therapy. In fact, hormone therapy is associated with a roughly 30% reduction in the incidence of new type 2 diabetes and modest improvements in HbA1c and fasting glucose in women already diagnosed. Transdermal estrogen is preferred in these patients.<\/p>\n<p>Well-controlled hypertension is also not a contraindication. Hormone therapy should not be initiated in the setting of <em>uncontrolled<\/em> hypertension, but once blood pressure is at goal, transdermal estrogen has a neutral effect on blood pressure and is safe.<\/p>\n<\/div>\n<p class=\"de-section\" id=\"sec-bone-health-and-osteoporosis-prevention\">Bone Health &amp; Osteoporosis Prevention<\/p>\n<p class=\"de-q\">How does hormone therapy protect my bones?<\/p>\n<div class=\"de-a\">\n<p>Estrogen suppresses bone resorption. Replacing it after menopause prevents the rapid bone loss that follows the final menstrual period and reduces the risk of osteoporotic fracture. The Women\u2019s Health Initiative \u2014 the largest randomized trial of hormone therapy ever conducted \u2014 showed roughly a 33% reduction in hip fracture and 35% reduction in vertebral fracture in women on combined estrogen-progestin therapy, and similar reductions with estrogen alone.<\/p>\n<p>For women within 10 years of menopause and under 60 with bothersome symptoms, fracture protection is a meaningful additional benefit. For women without symptoms but with risk factors for osteoporosis, hormone therapy can be considered for bone protection if other antiresorptive options are not preferred.<\/p>\n<div class=\"de-callout\">\n<strong>An important caveat:<\/strong> bone-specific medications such as bisphosphonates, denosumab, teriparatide, abaloparatide, and romosozumab are more effective than hormone therapy in women with established osteoporosis or very high fracture risk. Hormone therapy is preventive; it is not first-line for treating an existing diagnosis of osteoporosis.\n<\/div>\n<p>Lifestyle measures matter too: weight-bearing exercise, adequate calcium and vitamin D, fall prevention, and avoidance of tobacco and excessive alcohol.<\/p>\n<\/div>\n<p class=\"de-section\" id=\"sec-cancer-and-hormone-therapy\">Cancer &amp; Hormone Therapy<\/p>\n<p class=\"de-q\">Does hormone therapy cause breast cancer?<\/p>\n<div class=\"de-a\">\n<p>The honest answer is more nuanced than either the original 2002 headlines or the current \u201call clear\u201d social media take. The risk depends on the type of hormone therapy, the duration of use, the formulation of progestogen, and the woman\u2019s baseline risk.<\/p>\n<div class=\"table-wrap\">\n<table>\n<thead>\n<tr>\n<th>Regimen<\/th>\n<th>Effect on breast cancer risk<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Estrogen alone (women without a uterus)<\/td>\n<td>Neutral or slightly reduced risk in randomized data; some observational studies show a small increase. The WHI showed a non-significant <em>reduction<\/em> in breast cancer with estrogen alone over 7+ years.<\/td>\n<\/tr>\n<tr>\n<td>Estrogen plus progestogen (combined)<\/td>\n<td>Small increase in risk that grows with duration of use. The absolute risk is comparable to other modifiable risk factors such as obesity, alcohol, or low physical activity.<\/td>\n<\/tr>\n<tr>\n<td>Micronized progesterone or dydrogesterone<\/td>\n<td>Appears to carry less breast cancer risk than synthetic progestogens. These are our preferred choices when a progestogen is needed.<\/td>\n<\/tr>\n<tr>\n<td>Local vaginal estrogen<\/td>\n<td>No measurable increase in breast cancer risk. Safe even in many breast cancer survivors when non-hormonal therapies fail (in consultation with oncology).<\/td>\n<\/tr>\n<tr>\n<td>Hormone replacement in POI (under age 51)<\/td>\n<td>No increased risk above the age-adjusted general population risk.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>For context: the absolute increase in breast cancer risk with combined hormone therapy in the WHI was roughly 9 additional cases per 10,000 women per year. We discuss these numbers concretely with every patient before starting therapy. Personal and family history matter, and we adjust accordingly.<\/p>\n<\/div>\n<p class=\"de-q\">What if I have a history of breast cancer?<\/p>\n<div class=\"de-a\">\n<p>Systemic hormone therapy is not recommended in women with a history of breast cancer. Non-hormonal options for vasomotor symptoms, mood, and sleep should be tried first. For genitourinary symptoms \u2014 vaginal dryness, painful intercourse, urinary symptoms \u2014 non-hormonal lubricants and moisturizers are first-line. When these are insufficient, low-dose vaginal estrogen can be considered, and recent meta-analyses have not shown an increase in recurrence with this approach. Any such decision should be made jointly with the patient\u2019s oncologist.<\/p>\n<\/div>\n<p class=\"de-section\" id=\"sec-urogenital-and-sexual-health\">Urogenital &amp; Sexual Health<\/p>\n<p class=\"de-q\">What can be done about vaginal dryness, painful sex, and recurrent UTIs?<\/p>\n<div class=\"de-a\">\n<p>The genitourinary syndrome of menopause affects roughly half of postmenopausal women and, unlike hot flashes, it does not improve on its own. It includes vaginal dryness, burning, itching, painful intercourse, urinary urgency, and recurrent urinary tract infections. It responds extremely well to treatment, and it is dramatically undertreated.<\/p>\n<div class=\"treatment-item\">\n<div class=\"treatment-name\">Vaginal Moisturizers and Lubricants <span>Non-hormonal<\/span><\/div>\n<div class=\"treatment-body\">\n<p>Hyaluronic-acid- or polycarbophil-based moisturizers used several times a week, plus a quality lubricant for intercourse. Often sufficient for milder cases.<\/p>\n<\/div>\n<div style=\"border-top: 2px solid #1a1a1a; margin-bottom: 32px; position: relative;\"><span style=\"position: absolute; top: -12px; left: 0; background: #1a1a1a; color: #fff; font-size: 10px; font-weight: 700; letter-spacing: 0.18em; text-transform: uppercase; padding: 3px 12px; border-radius: 0 3px 3px 0;\">Hormone Therapy \u2014 A Closer Look<\/span><\/div>\n<\/div>\n<\/div>\n<p class=\"de-section\" id=\"sec-why-we-advocate-for-hormone-therapy\">Why We Advocate for Hormone Therapy<\/p>\n<p class=\"de-q\">Why has hormone therapy been so controversial?<\/p>\n<div class=\"de-a\">\n<p>In 2002, the Women\u2019s Health Initiative reported that combined estrogen-progestin therapy increased the risk of breast cancer, heart disease, and stroke. Use of hormone therapy fell by roughly half within six months. An entire generation of women \u2014 and their physicians \u2014 turned away from it.<\/p>\n<p>What followed in the years after has been less widely publicized: re-analyses of the same data exposed important limitations. The average woman in WHI was 63 years old and a full decade past menopause \u2014 already at meaningful baseline cardiovascular risk. The trial used one regimen \u2014 daily oral conjugated equine estrogens combined with medroxyprogesterone acetate \u2014 that has largely been replaced by transdermal estradiol and micronized progesterone in modern practice. When the WHI data are re-examined by age, women who started hormone therapy within 10 years of menopause did not show increased cardiovascular risk and showed a reduction in all-cause mortality.<\/p>\n<p>The current evidence has settled into a more nuanced picture: hormone therapy is the most effective treatment for vasomotor symptoms, prevents bone loss, treats the genitourinary syndrome, and \u2014 when started in the right window in the right patient \u2014 is safe. We think withholding it from a woman who would benefit is a bigger mistake than offering it.<\/p>\n<div class=\"de-warn\">\n<strong>The training gap is real.<\/strong> A 2023 survey found that more than 90% of obstetrics and gynecology residency program directors agreed that menopause should be a standardized part of training \u2014 but fewer than a third reported their programs actually offered such a curriculum. Many of the physicians women are seeing in their 40s and 50s simply have not been taught modern menopause management. We have made it a focus of our practice.<\/div>\n<\/div>\n<p class=\"de-section\" id=\"sec-how-hormone-therapy-is-given\">How Hormone Therapy Is Given<\/p>\n<p class=\"de-q\">What forms of hormone therapy are available?<\/p>\n<div class=\"de-a\">\n<p>The \u201cright\u201d hormone therapy is the one matched to the individual woman \u2014 her uterine status, her cardiovascular risk, her preference, and any contraindications. We have many options.<\/p>\n<div class=\"table-wrap\">\n<table>\n<thead>\n<tr>\n<th>Component<\/th>\n<th>Forms available<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Estrogen \u2014 transdermal<\/td>\n<td>Patch (e.g. estradiol), gel, spray. Preferred when cardiovascular risk, VTE risk, migraine with aura, or hypertriglyceridemia is present.<\/td>\n<\/tr>\n<tr>\n<td>Estrogen \u2014 oral<\/td>\n<td>Estradiol or conjugated equine estrogens. Effective and convenient; first-pass hepatic metabolism makes it less appropriate for some patients.<\/td>\n<\/tr>\n<tr>\n<td>Estrogen \u2014 vaginal<\/td>\n<td>Cream, tablet, soft-gel insert, ring. For genitourinary symptoms specifically.<\/td>\n<\/tr>\n<tr>\n<td>Progestogen (with estrogen, in women with a uterus)<\/td>\n<td>Micronized progesterone (preferred), dydrogesterone, or a levonorgestrel intrauterine device. Synthetic progestins are alternatives.<\/td>\n<\/tr>\n<tr>\n<td>Combination products<\/td>\n<td>Estradiol-progesterone capsules, estradiol-norethindrone patches, conjugated estrogens with bazedoxifene (which substitutes for a progestogen and protects the uterus).<\/td>\n<\/tr>\n<tr>\n<td>Tibolone<\/td>\n<td>A synthetic with mixed estrogenic, progestogenic, and androgenic activity. Available in many countries; useful in selected patients.<\/td>\n<\/tr>\n<tr>\n<td>Testosterone<\/td>\n<td>Off-label in the U.S. for hypoactive sexual desire disorder in postmenopausal women. Transdermal preferred. Levels monitored to stay in premenopausal range.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<p class=\"de-q\">Oral or transdermal \u2014 does it matter?<\/p>\n<div class=\"de-a\">\n<p>It often does. Oral estrogen passes through the liver before reaching the bloodstream, which raises clotting factors, triglycerides, and inflammatory markers. Transdermal estrogen bypasses this first-pass effect and has a more favorable cardiovascular and venous thrombosis profile.<\/p>\n<p>We usually prefer transdermal estrogen when any of the following are present: a personal or family history of venous thromboembolism, hypertension, controlled diabetes, obesity, hypertriglyceridemia, migraine with aura, or simply a desire to minimize cardiovascular risk. For a woman in her early 50s with no cardiovascular risk factors, oral and transdermal are both reasonable, and patient preference matters.<\/p>\n<\/div>\n<p class=\"de-q\">What about \u201cbioidentical\u201d or compounded hormones?<\/p>\n<div class=\"de-a\">\n<p>FDA-approved estradiol and micronized progesterone are <em>already bioidentical<\/em> \u2014 chemically identical to the hormones the ovary produces. They have undergone testing for safety, purity, and consistent dosing. We use them routinely.<\/p>\n<p>What is sometimes marketed as \u201cbioidentical hormone therapy\u201d \u2014 custom-compounded combinations of estradiol, estrone, estriol, DHEA, testosterone, and progesterone, often delivered as pellets, troches, or implants \u2014 is a different category. These products are not FDA-regulated, lack rigorous safety and pharmacokinetic data, and supraphysiologic dosing through pellets in particular has been associated with adverse effects. We recommend compounded preparations only when an FDA-approved option cannot meet a documented clinical need (such as a true allergy to a non-active ingredient).<\/p>\n<\/div>\n<p class=\"de-section\" id=\"sec-who-is-and-isn-t-a-candidate\">Who Is \u2014 and Isn\u2019t \u2014 a Candidate<\/p>\n<p class=\"de-q\">Am I a candidate for hormone therapy?<\/p>\n<div class=\"de-a\">\n<p>Most women with bothersome menopausal symptoms who initiate therapy within 10 years of menopause or before age 60 are good candidates. The risk-benefit profile is most favorable in this window \u2014 sometimes called the \u201ctiming hypothesis.\u201d<\/p>\n<p>Particularly strong indications include:<\/p>\n<div style=\"display: grid; grid-template-columns: 1fr 1fr; gap: 14px; margin: 16px 0;\">\n<div class=\"de-card\">\n<p style=\"margin-top:0;font-weight:600;color:#1a1a1a;font-size:1rem;\">Strong indications<\/p>\n<ul>\n<li>Moderate to severe hot flashes or night sweats<\/li>\n<li>Sleep disturbance from vasomotor symptoms<\/li>\n<li>Premature ovarian insufficiency or early menopause<\/li>\n<li>Genitourinary syndrome (local therapy)<\/li>\n<li>Bone loss in a woman within 10 years of menopause<\/li>\n<\/ul>\n<\/div>\n<div class=\"de-card\">\n<p style=\"margin-top:0;font-weight:600;color:#1a1a1a;font-size:1rem;\">Reasonable to consider<\/p>\n<ul>\n<li>Mood symptoms in perimenopause<\/li>\n<li>Quality-of-life-limiting symptoms not in the \u201cclassic\u201d list<\/li>\n<li>Prevention of bone loss with risk factors, no contraindications<\/li>\n<li>Surgical menopause<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<p class=\"de-q\">Who shouldn\u2019t take systemic hormone therapy?<\/p>\n<div class=\"de-a\">\n<p>Systemic hormone therapy is generally not appropriate in women with:<\/p>\n<ul style=\"margin: 12px 0 12px 20px; color: var(--mid); line-height: 1.8;\">\n<li>A history of breast cancer (vaginal estrogen may still be considered with oncology input)<\/li>\n<li>Active or recent venous thromboembolism, unless after individualized assessment with transdermal-only preparations<\/li>\n<li>Active or recent coronary artery disease, stroke, or transient ischemic attack<\/li>\n<li>Active liver disease<\/li>\n<li>Unexplained vaginal bleeding before evaluation<\/li>\n<li>Untreated endometrial hyperplasia or cancer<\/li>\n<li>Pregnancy<\/li>\n<\/ul>\n<p>For many of these patients, non-hormonal therapies \u2014 SSRIs\/SNRIs, gabapentin, NK3-receptor antagonists, cognitive behavioral therapy \u2014 can still meaningfully reduce symptoms. And for genitourinary symptoms specifically, low-dose vaginal estrogen is often safe even in many women who cannot use systemic therapy.<\/p>\n<div class=\"de-warn\">\n<strong>Hormone therapy is not used to prevent or treat dementia, and is not used for primary or secondary prevention of cardiovascular disease.<\/strong> These are not its indications. Symptom relief, prevention of bone loss, and treatment of the genitourinary syndrome are.<\/div>\n<\/div>\n<p class=\"de-section\" id=\"sec-monitoring-and-duration\">Monitoring &amp; Duration<\/p>\n<p class=\"de-q\">How long can I stay on hormone therapy?<\/p>\n<div class=\"de-a\">\n<p>There is no arbitrary cutoff. The decision to continue is made together \u2014 based on whether symptoms are still present, whether the benefit-risk balance still favors treatment, and what the patient prefers. Some women take hormone therapy for a few years to bridge through the worst of the transition. Others continue longer for ongoing symptom relief, bone protection, or quality of life.<\/p>\n<p>For women over 60, the conversation shifts somewhat \u2014 age itself raises the cardiovascular and breast cancer risks that hormone therapy can compound. We do not stop therapy reflexively at 60 or 65. We re-evaluate, often shift to a non-oral route at the lowest effective dose, and continue if benefit clearly exceeds risk.<\/p>\n<p>For women with premature ovarian insufficiency, hormone replacement should generally continue at least until the average age of natural menopause \u2014 around 51 \u2014 and then be reassessed.<\/p>\n<\/div>\n<p class=\"de-q\">What does follow-up look like?<\/p>\n<div class=\"de-a\">\n<p>We re-evaluate three months after starting therapy to confirm symptoms are controlled and the regimen is well tolerated. If symptoms persist or side effects develop, we adjust the dose, route, or progestogen \u2014 there are many options, and finding the right fit often takes one or two iterations.<\/p>\n<p>After that, follow-up is typically annual. We check blood pressure, weight, and changes in personal or family history. We continue routine breast cancer screening per national guidelines. We do not routinely check estradiol or FSH levels in women on hormone therapy for symptom control; symptoms are the better guide.<\/p>\n<\/div>\n<p class=\"de-section\" id=\"sec-a-final-note\">A Final Note<\/p>\n<p class=\"de-q\">Why does this conversation matter?<\/p>\n<div class=\"de-a\">\n<p>Roughly 1.3 million American women reach menopause every year. About a quarter experience symptoms severe enough to disrupt their lives. Many of them have been told that what they are experiencing is \u201cnormal aging,\u201d that hormone therapy is dangerous, or that they should simply wait it out.<\/p>\n<p>Modern menopause care is none of these things. It is rigorous, individualized, and effective. We treat menopause as the endocrine event it is \u2014 and we do not ask women to suffer through symptoms that we have safe, effective tools to address.<\/p>\n<div class=\"de-callout\">\n<strong>If you are experiencing symptoms \u2014 or if you have been told you \u201ccan\u2019t\u201d take hormone therapy and have never had a detailed conversation about why \u2014 we would welcome the chance to review your situation in detail.<\/strong><\/div>\n<\/div>\n<p>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row full_width=\u201dstretch_row\u201d css=\u201d.vc_custom_mp_hdr{background-color: #149d79 !important; padding-top: 28px !important; padding-bottom: 24px !important;}\u201d][vc_column][vc_custom_heading text=\u201dPatient Education \u00b7 Endocrinology\u201d font_container=\u201dtag:p|font_size:11px|text_align:left|color:%23ffffff\u201d use_theme_fonts=\u201dyes\u201d][vc_custom_heading text=\u201dMenopause &amp; Perimenopause\u201d font_container=\u201dtag:h1|font_size:44px|text_align:left|color:%23ffffff|line_height:1.1\u2033 use_theme_fonts=\u201dyes\u201d][vc_custom_heading text=\u201dA guide to understanding the menopause transition, the symptoms it brings, and the treatments \u2014 including hormone therapy \u2014 that we use to help our patients live well.\u201d font_container=\u201dtag:p|font_size:15px|text_align:left|color:%23ffffff\u201d use_theme_fonts=\u201dyes\u201d][\/vc_column][\/vc_row][vc_row][vc_column width=\u201d1\/1\u2033][vc_column_text] On this&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_gspb_post_css":"","footnotes":""},"class_list":["post-1016","page","type-page","status-publish","hentry","description-off"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Menopause &amp; Perimenopause - Diaendo<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Menopause &amp; Perimenopause - Diaendo\" \/>\n<meta property=\"og:description\" content=\"[vc_row full_width=\u201dstretch_row\u201d css=\u201d.vc_custom_mp_hdr{background-color: #149d79 !important; padding-top: 28px !important; padding-bottom: 24px !important;}\u201d][vc_column][vc_custom_heading text=\u201dPatient Education \u00b7 Endocrinology\u201d font_container=\u201dtag:p|font_size:11px|text_align:left|color:%23ffffff\u201d use_theme_fonts=\u201dyes\u201d][vc_custom_heading text=\u201dMenopause &amp; Perimenopause\u201d font_container=\u201dtag:h1|font_size:44px|text_align:left|color:%23ffffff|line_height:1.1\u2033 use_theme_fonts=\u201dyes\u201d][vc_custom_heading text=\u201dA guide to understanding the menopause transition, the symptoms it brings, and the treatments \u2014 including hormone therapy \u2014 that we use to help our patients live well.\u201d font_container=\u201dtag:p|font_size:15px|text_align:left|color:%23ffffff\u201d use_theme_fonts=\u201dyes\u201d][\/vc_column][\/vc_row][vc_row][vc_column width=\u201d1\/1\u2033][vc_column_text] On this&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/diaendo.com\/index.php\/menopause\/\" \/>\n<meta property=\"og:site_name\" content=\"Diaendo\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-30T22:49:55+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"18 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/diaendo.com\\\/index.php\\\/menopause\\\/\",\"url\":\"https:\\\/\\\/diaendo.com\\\/index.php\\\/menopause\\\/\",\"name\":\"Menopause & Perimenopause - Diaendo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/diaendo.com\\\/#website\"},\"datePublished\":\"2026-05-06T05:50:15+00:00\",\"dateModified\":\"2026-05-30T22:49:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/diaendo.com\\\/index.php\\\/menopause\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/diaendo.com\\\/index.php\\\/menopause\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/diaendo.com\\\/index.php\\\/menopause\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/diaendo.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Menopause &#038; Perimenopause\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/diaendo.com\\\/#website\",\"url\":\"https:\\\/\\\/diaendo.com\\\/\",\"name\":\"Diaendo\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/diaendo.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/diaendo.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/diaendo.com\\\/#organization\",\"name\":\"Diaendo\",\"url\":\"https:\\\/\\\/diaendo.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/diaendo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/diaendo.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Logo-DES-Only-e1776570089619.jpg\",\"contentUrl\":\"https:\\\/\\\/diaendo.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Logo-DES-Only-e1776570089619.jpg\",\"width\":266,\"height\":228,\"caption\":\"Diaendo\"},\"image\":{\"@id\":\"https:\\\/\\\/diaendo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Menopause & Perimenopause - Diaendo","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Menopause & Perimenopause - Diaendo","og_description":"[vc_row full_width=\u201dstretch_row\u201d css=\u201d.vc_custom_mp_hdr{background-color: #149d79 !important; padding-top: 28px !important; padding-bottom: 24px !important;}\u201d][vc_column][vc_custom_heading text=\u201dPatient Education \u00b7 Endocrinology\u201d font_container=\u201dtag:p|font_size:11px|text_align:left|color:%23ffffff\u201d use_theme_fonts=\u201dyes\u201d][vc_custom_heading text=\u201dMenopause &amp; Perimenopause\u201d font_container=\u201dtag:h1|font_size:44px|text_align:left|color:%23ffffff|line_height:1.1\u2033 use_theme_fonts=\u201dyes\u201d][vc_custom_heading text=\u201dA guide to understanding the menopause transition, the symptoms it brings, and the treatments \u2014 including hormone therapy \u2014 that we use to help our patients live well.\u201d font_container=\u201dtag:p|font_size:15px|text_align:left|color:%23ffffff\u201d use_theme_fonts=\u201dyes\u201d][\/vc_column][\/vc_row][vc_row][vc_column width=\u201d1\/1\u2033][vc_column_text] On this&hellip;","og_url":"https:\/\/diaendo.com\/index.php\/menopause\/","og_site_name":"Diaendo","article_modified_time":"2026-05-30T22:49:55+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"18 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/diaendo.com\/index.php\/menopause\/","url":"https:\/\/diaendo.com\/index.php\/menopause\/","name":"Menopause & Perimenopause - Diaendo","isPartOf":{"@id":"https:\/\/diaendo.com\/#website"},"datePublished":"2026-05-06T05:50:15+00:00","dateModified":"2026-05-30T22:49:55+00:00","breadcrumb":{"@id":"https:\/\/diaendo.com\/index.php\/menopause\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/diaendo.com\/index.php\/menopause\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/diaendo.com\/index.php\/menopause\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/diaendo.com\/"},{"@type":"ListItem","position":2,"name":"Menopause &#038; Perimenopause"}]},{"@type":"WebSite","@id":"https:\/\/diaendo.com\/#website","url":"https:\/\/diaendo.com\/","name":"Diaendo","description":"","publisher":{"@id":"https:\/\/diaendo.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/diaendo.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/diaendo.com\/#organization","name":"Diaendo","url":"https:\/\/diaendo.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/diaendo.com\/#\/schema\/logo\/image\/","url":"https:\/\/diaendo.com\/wp-content\/uploads\/2025\/04\/Logo-DES-Only-e1776570089619.jpg","contentUrl":"https:\/\/diaendo.com\/wp-content\/uploads\/2025\/04\/Logo-DES-Only-e1776570089619.jpg","width":266,"height":228,"caption":"Diaendo"},"image":{"@id":"https:\/\/diaendo.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/diaendo.com\/index.php\/wp-json\/wp\/v2\/pages\/1016","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/diaendo.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/diaendo.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/diaendo.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/diaendo.com\/index.php\/wp-json\/wp\/v2\/comments?post=1016"}],"version-history":[{"count":13,"href":"https:\/\/diaendo.com\/index.php\/wp-json\/wp\/v2\/pages\/1016\/revisions"}],"predecessor-version":[{"id":1214,"href":"https:\/\/diaendo.com\/index.php\/wp-json\/wp\/v2\/pages\/1016\/revisions\/1214"}],"wp:attachment":[{"href":"https:\/\/diaendo.com\/index.php\/wp-json\/wp\/v2\/media?parent=1016"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}